Biotech company developing orally delivered enzymes for metabolic diseases.
Company had an asset efficacious in several metabolic diseases. They needed to prioritize and focus their funds, while maximizing the company value. The company was also actively fundraising and needed clear indication prioritization to attract the right investors, while insuring competitive advantages in the market.
We took a systematic approach to indication prioritization by developing a target product profile (TPP) for the lead asset. We conducted in-depth interviews with physicians, payors and investigators in the areas of interest to inform our analysis.
The TPP also provided clear use of proceeds for the next clinical stage of development and informed the experimental roadmap to preclinically validate new claims identified in the TPP.
The TPP helped formulate clear product development strategy, select lead indication and best position the company for fundraising.
Radyus Related Services:
+ Target product profile
+ Indication selection
+ Fundraising strategy